SCHEMBL8935274

SCHEMBL8935274

CCCCN1CCC(Oc2cc3cc[nH]c(=O)c3cc2F)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44
ROCK1 Q13464 5/20 0.44
MAP2K1 Q02750 1/20 0.43
ACHE P22303 1/20 0.43
HTR4 Q13639 1/20 0.43
PARP1 P09874 1/20 0.41
HRH3 Q9Y5N1 1/20 0.40
ROCK2 O75116 1/20 0.39
PRKACA P17612 1/20 0.39
PRKCD Q05655 1/20 0.39
PRKG1 Q13976 1/20 0.39
PKN1 Q16512 1/20 0.39
PKN2 Q16513 1/20 0.39
AAK1 Q2M2I8 1/20 0.39
CDC42BPA Q5VT25 1/20 0.39
Q6ZSR9 Q6ZSR9 1/20 0.39
BMP2K Q9NSY1 1/20 0.39
CDC42BPB Q9Y5S2 1/20 0.39
DRD2 P14416 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8935067 0.94 ROCK1 (0.45) ROCK1MAP2K1PARP1HRH3ROCK2
SCHEMBL8938067 0.89 ROCK1 (0.57) MAOAMAOBROCK1MAP2K1ACHE
SCHEMBL8934924 0.88 MAP2K1 (0.58) MAOAMAOBROCK1MAP2K1ACHE
SCHEMBL8935387 0.84 ROCK1 (0.44) ROCK1MAP2K1HRH3ROCK2PRKACA
SCHEMBL8935064 0.84 MAP2K1 (0.45) ROCK1MAP2K1ACHEHTR4HRH3
SCHEMBL8938071 0.82 ROCK1 (0.59) MAOAMAOBROCK1MAP2K1PARP1
SCHEMBL8934752 0.82 ROCK1 (0.61) MAOAMAOBROCK1MAP2K1ACHE
SCHEMBL8937313 0.82 MAOA (0.42) MAOAMAOBPARP1HRH3DRD2
SCHEMBL8934906 0.81 MAP2K1 (0.60) ROCK1MAP2K1HTR4PARP1HRH3
SCHEMBL8935394 0.81 HRH3 (0.49) ROCK1MAP2K1HRH3ROCK2PRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2385047-B1 Piperidinyl-substituted isoquinolone derivatives SANOFI SA (FR) 2013-05-29 EP disclosed
US-8188117-B2 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-8188117-B2 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
EP-2385047-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI (FR) 2011-11-09 EP disclosed
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2009-04-09 US disclosed
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives MYLK2, MYLK, RHOT2 MAOA 2633/4885MAOB 2595/4885ROCK1 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.